With the inclusion of new sites and countries, the REMAP-CAP family continues to grow. WE4YOU is a 45 minutes montly webinar on Wednesdays at 16:00 (Amsterdam time) to keep you up to date and exchange knowledge on all that is REMAP-CAP. A different topic is presented each webinar after which there is panel discussion where you can have your questions answered by REMAP-CAP experts.
We look forward to seeing you there! Contact us at eu.remap@umcutrecht.nl for any questions
Accessibility
Cookies
Data protection
Help using our website
Terms and conditions
Europe University Medical Center, Utrecht Heidelberglaan 100 3584 CX, The Netherlands
Email: EU.remapcap@umcutrecht.nl
Tel: +31 88 75 551 96
REMAP-CAP ClinicalTrials.gov registration NCT02735707
REMAP-CAP EU Clinical Trials Register EudraCT number: 2015-002340-14
UMC Utrecht is the Sponsor for the trial in Europe and some countries outside Europe.
Sponsor is a consortium member in the project “Rapid European COVID-19 Emergency Research Response (RECOVER)” funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589.
Inseparable to the design of this trial, platform conclusions are generated through frequent adaptive analyses as data accrues. To date, REMAP-CAP has contributed to the knowledge about the best treatment of COVID-19 with several results:
ACE2 RAS DOMAIN (27 Feb 2022)
Antiplatelet DOMAIN (23 Jun 2021)
CORTICOSTEROID DOMAIN
COVID-19 IMMUNE MODULATION DOMAIN
COVID-19 ANTI-COAGULATION DOMAIN
COVID-19 IMMUNOGLOBULIN DOMAIN
COVID-19 ANTIVIRAL DOMAIN